Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Minwei Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9902-2183; OpenAlex author ID A5091122364. Sources: OpenAlex.

Their work

Papers
44 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
97
Papers, trials and grants by year

2015: 2 papers · 2016: 4 papers · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 4 papers · 2024: 6 papers · 2025: 2 papers · 2026: 5 papers

Papers 44

  1. Nerve-proximal tertiary lymphoid structures predict chemotherapy sensitivity in pancreatic cancer. First author DOI 10.1016/j.celrep.2026.117496↗
  2. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  3. Retraction: Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.28909↗
  4. L-Lactate reprograms tumor-associated macrophages to drive pancreatic cancer progression via BCL3 lactylation Co-author DOI 10.64898/2026.03.06.710237↗
  5. OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.7150/ijbs.125552↗
  6. Serum microRNA-24-based nomogram predicts prognosis for patients with resected pancreatic cancer. Co-author DOI 10.1038/s41598-024-82369-9↗
  7. TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis. Co-author DOI 10.7150/ijbs.104598↗
  8. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. Co-author DOI 10.1007/s10620-024-08338-4↗
  9. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  10. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. First author DOI 10.1016/j.canlet.2024.217130↗
  11. Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospective analysis. Co-author DOI 10.1016/j.canlet.2024.217213↗
  12. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  13. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  14. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  15. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  16. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
  17. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  18. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  19. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  20. HOXA10 promote pancreatic cancer progression via directly activating canonical NF-κB signaling pathway. Co-author DOI 10.1093/carcin/bgac042↗
  21. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  22. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  23. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  24. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  25. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  26. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  27. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  28. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  29. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Co-author DOI 10.7150/thno.45124↗
  30. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.051↗
  31. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  32. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  33. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  34. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗
  35. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-018-34094-3↗
  36. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3131↗
  37. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  38. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  39. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  40. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  41. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  42. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗
  43. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-015-0202-1↗
  44. High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma. First author PMID 26550461↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 35 shared papers, 2015–2026 · strength 4.16
  2. Yan‐Miao Huo · 29 shared papers, 2015–2026 · strength 3.30
  3. Jian‐Yu Yang · 24 shared papers, 2015–2026 · strength 2.63
  4. Xueliang Fu · 23 shared papers, 2015–2026 · strength 2.42
  5. Shu‐Heng Jiang · 15 shared papers, 2016–2026 · strength 2.15
  6. Dejun Liu · 17 shared papers, 2015–2024 · strength 1.75
  7. Rong Hua · 19 shared papers, 2015–2024 · strength 1.71
  8. Zhigang Zhang · 13 shared papers, 2016–2026 · strength 1.47
  9. Junfeng Zhang · 11 shared papers, 2016–2026 · strength 1.21
  10. Jia-Hao Zheng · 7 shared papers, 2022–2026 · strength 1.20
  11. Hong‐Fei Yao · 7 shared papers, 2022–2025 · strength 1.20
  12. Ruizhe He · 10 shared papers, 2018–2023 · strength 1.13
  13. Zong‐Hao Duan · 5 shared papers, 2024–2026 · strength 1.07
  14. Li-Peng Hu · 8 shared papers, 2018–2024 · strength 1.02
  15. Qin-Yuan Jia · 4 shared papers, 2023–2025 · strength 0.73
  16. Wei Liu · 4 shared papers, 2020–2026 · strength 0.72
  17. Qing Li · 6 shared papers, 2018–2024 · strength 0.71
  18. Ping Lu · 6 shared papers, 2018–2024 · strength 0.66
  19. Junfeng Zhang · 7 shared papers, 2015–2022 · strength 0.65
  20. Jing Xue · 6 shared papers, 2018–2024 · strength 0.65
  21. Yong-Wei Sun · 3 shared papers, 2024–2026 · strength 0.64
  22. Gary Guishan Xiao · 4 shared papers, 2020–2025 · strength 0.61
  23. Linli Yao · 4 shared papers, 2021–2026 · strength 0.61
  24. Wei Chiang Liu · 6 shared papers, 2016–2022 · strength 0.61
  25. Ningning Niu · 4 shared papers, 2019–2024 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.